Despite the effectiveness of triple drug combinations in anti-HIV chemotherapy, there are still several critical issues remaining to be resolved in HIV chemotherapy. The first issue is the viral reservoir. Triple combination therapy (two nucleoside reverse transcriptase inhibitors plus one protease inhibitor) can virtually eliminate the HIV viral load to undetectable level in the serum in many HIV patients who are undergoing therapy. There are at least two other major compartments which should be considered: the central nervous and the lymphatic system. In this application, Dr. Chu will continue to study these two systems with some proposed prodrugs to improve their pharmacokinetics/ pharmacodynamic profiles. If any prodrugs are found to be promising during these studies, the focus will be on them to determine their potential as clinical candidates. Studies will include pharmacokinetic/pharmacodynamic studies in mice, rats and rhesus monkeys. In view of the number of children born with HIV infection, another area of focus is the maternal-fetal drug delivery issue which will be investigated using a rat model. Additionally, as drug interactions have become an increasingly important issue in HIV chemotherapy this will also be studied in vitro and in animal models to provide information on cellular, virological, pharmacological and toxicological interactions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI025899-14
Application #
6169881
Study Section
AIDS and Related Research Study Section 4 (ARRD)
Program Officer
Litterst, Charles L
Project Start
1987-09-30
Project End
2001-06-30
Budget Start
2000-05-01
Budget End
2001-06-30
Support Year
14
Fiscal Year
2000
Total Cost
$353,514
Indirect Cost
Name
University of Georgia
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Athens
State
GA
Country
United States
Zip Code
30602
Rawal, Ravindra K; Singh, Uma S; Chavre, Satish N et al. (2013) 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. Bioorg Med Chem Lett 23:503-6
Friedman, Julia; Cho, Won-Kyung; Chu, Chung K et al. (2011) Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 85:9078-89
Wang, Jianing; Singh, Uma S; Rawal, Ravindra K et al. (2011) Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. Bioorg Med Chem Lett 21:6328-31
Gadthula, Srinivas; Rawal, Ravindra K; Sharon, Ashoke et al. (2011) Synthesis and antiviral activity of cyclopropyl-spirocarbocyclic adenosine, (4R,5S,6R,7R)-4-(6-amino-9H-purin-9-yl)-7-(hydroxymethyl)spiro[2.4]heptane-5,6-diol against hepatitis C virus. Bioorg Med Chem Lett 21:3982-5
Sharon, Ashoke; Chu, Chung K (2008) Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 80:339-53
Liang, Yuzeng; Narayanasamy, Janarthanan; Schinazi, Raymond F et al. (2006) Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies. Bioorg Med Chem 14:2178-89
Liang, Yuzeng; Narayanasamy, Janarthanan; Rapp, Kim L et al. (2006) PAMAM dendrimers and branched polyethyleneglycol (nanoparticles) prodrugs of (-)-beta-D-(2R, 4R)-dioxolane-thymine (DOT) and their anti-HIV activity. Antivir Chem Chemother 17:321-9
Shi, Junxing; Du, Jinfa; Ma, Tianwei et al. (2005) Synthesis and in vitro anti-HCV activity of beta-D- and 1-2'-deoxy-2'-fluororibonucleosides. Nucleosides Nucleotides Nucleic Acids 24:875-9
Ray, Adrian S; Hernandez-Santiago, Brenda I; Mathew, Judy S et al. (2005) Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine. Antimicrob Agents Chemother 49:1994-2001
Wang, Jianing; Jin, Yunho; Rapp, Kimberly L et al. (2005) Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. J Med Chem 48:3736-48

Showing the most recent 10 out of 88 publications